Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | SERPINE1 | P05121 | 10/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269119 | 0.89 | F10 (0.55) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL274496 | 0.87 | NPC1 (0.54) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL268333 | 0.86 | ACHE (0.52) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL6351321 | 0.79 | SERPINE1 (0.89) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL6348409 | 0.78 | AKR1C4 (0.66) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL6352581 | 0.78 | AKR1C4 (0.78) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL415869 | 0.77 | SERPINE1 (1.00) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL6349319 | 0.77 | SERPINE1 (0.85) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 | |
| SCHEMBL265628 | 0.77 | SLC34A2 (0.51) | AKR1C4AKR1C3AKR1C2AKR1C1ACHE | |
| SCHEMBL6346584 | 0.76 | AKR1C2 (0.63) | AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | AKR1C4 551/4885AKR1C3 289/4885AKR1C2 386/4885 |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | AKR1C4 883/4885AKR1C3 461/4885AKR1C2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.